These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19684507)

  • 41. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy.
    Overton ET; Nurutdinova D; Freeman J; Seyfried W; Mondy KE
    HIV Med; 2009 Jul; 10(6):343-50. PubMed ID: 19490182
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?
    Poveda E; Crespo M
    AIDS Rev; 2018; 20(1):71-72. PubMed ID: 29628513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
    Rossi C; Raboud J; Walmsley S; Cooper C; Antoniou T; Burchell AN; Hull M; Chia J; Hogg RS; Moodie EE; Klein MB;
    BMC Infect Dis; 2017 Apr; 17(1):246. PubMed ID: 28376824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy.
    Calza L; Sachs M; Colangeli V; Borderi M; Granozzi B; Malosso P; Comai G; Corradetti V; La Manna G; Viale P
    Clin Exp Nephrol; 2019 Nov; 23(11):1272-1279. PubMed ID: 31327092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
    Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women.
    Estrella MM; Parekh RS; Abraham A; Astor BC; Szczech LA; Anastos K; Dehovitz JA; Merenstein DJ; Pearce CL; Tien PC; Cohen MH; Gange SJ
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):217-20. PubMed ID: 20581688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
    Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
    JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kidney disease risk factors associate with urine biomarkers concentrations in HIV-positive persons; a cross-sectional study.
    Muiru AN; Shlipak MG; Scherzer R; Zhang WR; Ascher SB; Jotwani V; Grunfeld C; Parikh CR; Ng D; Palella FJ; Ho K; Kassaye S; Sharma A; Cohen M; Wang R; Qi Q; Estrella MM
    BMC Nephrol; 2019 Jan; 20(1):4. PubMed ID: 30606136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification.
    Sklar PA; Ward DJ; Baker RK; Wood KC; Gafoor Z; Alzola CF; Moorman AC; Holmberg SD;
    AIDS; 2002 Oct; 16(15):2035-41. PubMed ID: 12370502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Associations of Urine Biomarkers with Kidney Function Decline in HIV-Infected and Uninfected Men.
    Ascher SB; Scherzer R; Estrella MM; Shlipak MG; Ng DK; Palella FJ; Witt MD; Ho K; Bennett MR; Parikh CR; Ix JH; Jotwani V
    Am J Nephrol; 2019; 50(5):401-410. PubMed ID: 31553981
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence and risk factors for acute kidney injury in HIV Infection.
    Li Y; Shlipak MG; Grunfeld C; Choi AI
    Am J Nephrol; 2012; 35(4):327-34. PubMed ID: 22456100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.
    Sabin CA; Yee TT; Devereux H; Griffioen A; Loveday C; Phillips AN; Lee CA
    AIDS; 2000 May; 14(8):1001-7. PubMed ID: 10853982
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiretroviral-treated HIV-infected women have similar long-term kidney function trajectories as HIV-uninfected women.
    Estrella MM; Abraham AG; Jing Y; Parekh RS; Tien PC; Merenstein D; Pearce CL; Anastos K; Cohen MH; Dehovitz JA; Gange SJ
    AIDS Res Hum Retroviruses; 2013 May; 29(5):755-60. PubMed ID: 23273313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine.
    Casado JL; Monsalvo M; Vizcarra P; Fontecha M; Serrano-Villar S; Moreno S
    HIV Med; 2019 Nov; 20(10):648-656. PubMed ID: 31321875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1.73 m2.
    Fafin C; Pugliese P; Durant J; Mondain V; Rahelinirina V; De Salvador F; Ceppi C; Perbost I; Rosenthal E; Roger PM; Cua E; Dellamonica P; Esnault V; Pradier C; Moranne O
    Nephron Clin Pract; 2012; 120(4):c205-14. PubMed ID: 23037894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
    Teira R; Vidal F; Muñoz-Sánchez P; Geijo P; Viciana P; Ribera E; Domingo P; Castaño M; Martínez E; Roca B; Puig T; Estrada V; Deig E; Galindo MJ; de la Fuente B; Lozano F; Montero M; Muñoz-Sanz A; Sanchez T; Terrón A; Romero-Palacios A; Lacalle JR; Garrido M; Suárez-Lozano I;
    HIV Med; 2017 Mar; 18(3):196-203. PubMed ID: 27476742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
    Pernas B; Grandal M; Pertega S; Cañizares A; Castro-Iglesias Á; Mena Á; Rodriguez-Osorio I; Tabernilla A; Pedreira JD; Poveda E
    J Antimicrob Chemother; 2016 Apr; 71(4):1051-5. PubMed ID: 26702924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.